ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Looking at Q1 Corti vs Acthar sales. The combined sales grew by over $41.4 million over Q1 2023 with ANIP capturing approx. 50% of the revenue growth. Seeing that Corti sells for approximately $10,000 less. ANIP is obviously capturing more than 50% of the new prescriptions. This bodes well for ANIP as Nikhil believes the ACTH therapy market is headed back to over $1.2 billion.